Drug Profile
Research programme: neuropsychiatric disorder therapies - Teva Pharmaceutical Industries/PsychoGenics
Latest Information Update: 09 Apr 2010
Price :
$50
*
At a glance
- Originator Cephalon; PsychoGenics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Psychiatric disorders